Hmdb loader
Survey
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2013-07-04 19:04:52 UTC
Update Date2021-09-14 15:00:01 UTC
HMDB IDHMDB0060872
Secondary Accession Numbers
  • HMDB60872
Metabolite Identification
Common NameSorafenib beta-D-Glucuronide
DescriptionSorafenib beta-D-Glucuronide belongs to the class of organic compounds known as n-glucuronides. These are glucuronides in which the aglycone is linked to the carbohydrate unit through a N-glycosidic bond. Sorafenib beta-D-Glucuronide is a moderately basic compound (based on its pKa).
Structure
Data?1563866116
Synonyms
ValueSource
Sorafenib b-D-glucuronideGenerator
Sorafenib β-D-glucuronideGenerator
Chemical FormulaC27H24ClF3N4O9
Average Molecular Weight640.949
Monoisotopic Molecular Weight640.118390708
IUPAC Name(2S,3S,4S,5R,6R)-6-{1-[4-chloro-3-(trifluoromethyl)phenyl][(4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phenyl)carbamoyl]amino}-3,4,5-trihydroxyoxane-2-carboxylic acid
Traditional Name(2S,3S,4S,5R,6R)-6-{1-[4-chloro-3-(trifluoromethyl)phenyl][(4-{[2-(methylcarbamoyl)pyridin-4-yl]oxy}phenyl)carbamoyl]amino}-3,4,5-trihydroxyoxane-2-carboxylic acid
CAS Registry NumberNot Available
SMILES
CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)N([C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)C3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
InChI Identifier
InChI=1S/C27H24ClF3N4O9/c1-32-23(39)18-11-15(8-9-33-18)43-14-5-2-12(3-6-14)34-26(42)35(13-4-7-17(28)16(10-13)27(29,30)31)24-21(38)19(36)20(37)22(44-24)25(40)41/h2-11,19-22,24,36-38H,1H3,(H,32,39)(H,34,42)(H,40,41)/t19-,20-,21+,22-,24+/m0/s1
InChI KeyHALZWBPBJOJUOZ-QMDPOKHVSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as n-glucuronides. These are glucuronides in which the aglycone is linked to the carbohydrate unit through a N-glycosidic bond.
KingdomOrganic compounds
Super ClassOrganic oxygen compounds
ClassOrganooxygen compounds
Sub ClassCarbohydrates and carbohydrate conjugates
Direct ParentN-glucuronides
Alternative Parents
Substituents
  • 1-n-glucuronide
  • N-glucuronide
  • Hexose monosaccharide
  • Diaryl ether
  • Glycosyl compound
  • N-glycosyl compound
  • N-phenylurea
  • Trifluoromethylbenzene
  • Pyridine carboxylic acid or derivatives
  • 2-heteroaryl carboxamide
  • Phenoxy compound
  • Phenol ether
  • Beta-hydroxy acid
  • Chlorobenzene
  • Halobenzene
  • Pyridine
  • Pyran
  • Hydroxy acid
  • Aryl chloride
  • Oxane
  • Monosaccharide
  • Aryl halide
  • Monocyclic benzene moiety
  • Benzenoid
  • Heteroaromatic compound
  • Carboxamide group
  • Urea
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carbonic acid derivative
  • Carboxylic acid derivative
  • Carboxylic acid
  • Oxacycle
  • Azacycle
  • Ether
  • Organoheterocyclic compound
  • Polyol
  • Monocarboxylic acid or derivatives
  • Organochloride
  • Organohalogen compound
  • Organic nitrogen compound
  • Alcohol
  • Carbonyl group
  • Organofluoride
  • Organonitrogen compound
  • Organopnictogen compound
  • Alkyl fluoride
  • Alkyl halide
  • Organic oxide
  • Hydrocarbon derivative
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Ontology
Physiological effectNot Available
Disposition
Process
RoleNot Available
Physical Properties
StateNot Available
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water SolubilityNot AvailableNot Available
LogPNot AvailableNot Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.057 g/LALOGPS
logP2.69ALOGPS
logP1.93ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.44ChemAxon
pKa (Strongest Basic)2.01ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area190.78 ŲChemAxon
Rotatable Bond Count8ChemAxon
Refractivity145.16 m³·mol⁻¹ChemAxon
Polarizability57.42 ųChemAxon
Number of Rings4ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+241.78730932474
DeepCCS[M-H]-240.13330932474
DeepCCS[M-2H]-274.1730932474
DeepCCS[M+Na]+247.94430932474
AllCCS[M+H]+232.932859911
AllCCS[M+H-H2O]+231.932859911
AllCCS[M+NH4]+233.732859911
AllCCS[M+Na]+234.032859911
AllCCS[M-H]-226.932859911
AllCCS[M+Na-2H]-228.532859911
AllCCS[M+HCOO]-230.432859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
Sorafenib beta-D-GlucuronideCNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)N([C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)C3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C15813.9Standard polar33892256
Sorafenib beta-D-GlucuronideCNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)N([C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)C3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C13755.0Standard non polar33892256
Sorafenib beta-D-GlucuronideCNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)N([C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)C3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C14951.1Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Sorafenib beta-D-Glucuronide,1TMS,isomer #1CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N14686.0Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TMS,isomer #2CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N14660.4Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TMS,isomer #3CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N14677.5Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TMS,isomer #4CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N14665.5Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TMS,isomer #5CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C4728.7Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TMS,isomer #6CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N14471.3Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #1CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N14633.8Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #10CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N14616.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #11CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4640.4Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #12CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N14417.7Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #13CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C4622.3Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #14CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N14406.0Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #15CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4427.9Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #2CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N14633.0Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #3CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N14622.2Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #4CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C4652.4Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #5CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N14422.5Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #6CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N14607.7Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #7CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)C=C2)=CC=N14616.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #8CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C4627.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TMS,isomer #9CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N14416.4Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #1CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N14587.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #10CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4389.9Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #11CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)C=C2)=CC=N14579.0Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #12CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C4568.5Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #13CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N14395.8Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #14CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4586.7Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #15CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N14396.8Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #16CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4379.7Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #17CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4573.5Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #18CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N14389.6Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #19CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4382.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #2CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N14582.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #20CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4368.4Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #3CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C4592.0Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #4CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N14401.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #5CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O[Si](C)(C)C)C=C2)=CC=N14599.6Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #6CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C4604.5Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #7CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O[Si](C)(C)C)[C@H]3O)[Si](C)(C)C)C=C2)=CC=N14405.9Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #8CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C)C=C2)=CC=N1)[Si](C)(C)C4603.9Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,3TMS,isomer #9CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C)[Si](C)(C)C)C=C2)=CC=N14397.6Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TBDMS,isomer #1CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N14849.4Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TBDMS,isomer #2CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)C=C2)=CC=N14841.8Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TBDMS,isomer #3CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N14847.7Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TBDMS,isomer #4CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N14859.5Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TBDMS,isomer #5CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C4978.8Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,1TBDMS,isomer #6CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N14653.8Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #1CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N14970.9Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #10CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N14965.3Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #11CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C5035.6Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #12CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)=CC=N14771.6Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #13CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C5047.4Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #14CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N14780.5Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #15CN(C(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C4852.3Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #2CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)C=C2)=CC=N14959.2Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #3CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N14961.2Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #4CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C5039.7Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #5CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N14766.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #6CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O[Si](C)(C)C(C)(C)C)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)C=C2)=CC=N14957.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #7CNC(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O[Si](C)(C)C(C)(C)C)C=C2)=CC=N14944.4Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #8CN(C(=O)C1=CC(OC2=CC=C(NC(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)C=C2)=CC=N1)[Si](C)(C)C(C)(C)C5026.1Semi standard non polar33892256
Sorafenib beta-D-Glucuronide,2TBDMS,isomer #9CNC(=O)C1=CC(OC2=CC=C(N(C(=O)N(C3=CC=C(Cl)C(C(F)(F)F)=C3)[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]3O)[Si](C)(C)C(C)(C)C)C=C2)=CC=N14762.1Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (Non-derivatized) - 70eV, Positivesplash10-000i-9322163000-54fb357763970483dd0d2017-09-20Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_1) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_2) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_3) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_4) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_5) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_1_6) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_1) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_2) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_3) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_4) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_5) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_6) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_7) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_8) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_9) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_10) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_11) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_12) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_13) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_14) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_2_15) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_3_1) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_3_2) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Sorafenib beta-D-Glucuronide GC-MS (TMS_3_3) - 70eV, PositiveNot Available2021-10-17Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 10V, Positive-QTOFsplash10-014i-0001904000-77afae7c5dd756d9a3f92017-10-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 20V, Positive-QTOFsplash10-0lk9-1134900000-1bffc1070bb835e1fba32017-10-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 40V, Positive-QTOFsplash10-0a4i-0133900000-71962cb0bba5f185f9552017-10-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 10V, Negative-QTOFsplash10-03dr-0151968000-0cc0bb024009b1d9b6132017-10-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 20V, Negative-QTOFsplash10-03di-0140950000-9e5b40a4b46a004f059c2017-10-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 40V, Negative-QTOFsplash10-0006-4792500000-a80511e6b557923dfacf2017-10-06Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 10V, Negative-QTOFsplash10-0kg9-0138139000-e1f389ba05fd6d003fba2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 20V, Negative-QTOFsplash10-0a4l-6110294000-e0f30f817ff676b5381f2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 40V, Negative-QTOFsplash10-0006-9713203000-71ac59636f4d397c3bae2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 10V, Positive-QTOFsplash10-00dl-0002109000-62f8e1c06fa311179cfa2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 20V, Positive-QTOFsplash10-014i-0000933000-35c30825c89c1f04e4af2021-10-12Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Sorafenib beta-D-Glucuronide 40V, Positive-QTOFsplash10-069c-0321942000-844e398ad2337b1e0e042021-10-12Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
Biospecimen Locations
  • Blood
  • Urine
Tissue Locations
  • Kidney
  • Liver
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableNormal
      Not Available
details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableNormal
      Not Available
details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDNot Available
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider IDNot Available
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkNot Available
METLIN IDNot Available
PubChem Compound71752221
PDB IDNot Available
ChEBI IDNot Available
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General ReferencesNot Available